Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ 349 Cr.
- Current Price ₹ 42.1
- High / Low ₹ 57.0 / 30.2
- Stock P/E 25.3
- Book Value ₹ 9.10
- Dividend Yield 0.00 %
- ROCE 23.1 %
- ROE 19.0 %
- Face Value ₹ 2.00
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 38.3% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.0% over past five years.
- Earnings include an other income of Rs.6.44 Cr.
- Promoter holding has decreased over last 3 years: -12.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 145 | 151 | 206 | 238 | |
| 48 | 63 | 50 | 58 | 95 | 86 | 117 | 114 | 131 | 132 | 136 | 189 | 220 | |
| Operating Profit | 3 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 10 | 13 | 15 | 17 | 18 |
| OPM % | 6% | 5% | 7% | 6% | 2.8% | 3.2% | 4.3% | 6% | 7% | 9% | 10% | 8% | 7% |
| 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 3 | 6 | 6 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 6 | 10 | 11 | 14 | 18 | 19 |
| Tax % | 28% | 40% | 4% | 35% | 28% | 26% | 30% | 26% | 28% | 27% | 25% | 27% | |
| 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | 13 | 14 | |
| EPS in Rs | 0.25 | 0.35 | 0.25 | 0.15 | 0.19 | 0.20 | 0.31 | 0.58 | 0.87 | 1.00 | 1.22 | 1.58 | 1.67 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 11% |
| 3 Years: | 14% |
| TTM: | 50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 38% |
| 3 Years: | 22% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | -19% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 19% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 12 | 13 | 13 | 23 | 24 | 26 | 28 | 20 | 27 | 36 | 46 | 59 |
| 8 | 14 | 19 | 13 | 14 | 14 | 15 | 13 | 10 | 8 | 15 | 19 | |
| 14 | 17 | 13 | 20 | 35 | 32 | 28 | 28 | 34 | 36 | 43 | 59 | |
| Total Liabilities | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 | 153 |
| 8 | 7 | 7 | 7 | 12 | 13 | 15 | 18 | 22 | 21 | 21 | 20 | |
| CWIP | 0 | 0 | 3 | 4 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 |
| 27 | 38 | 39 | 48 | 63 | 60 | 59 | 59 | 64 | 73 | 96 | 129 | |
| Total Assets | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 | 153 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3 | 5 | 5 | 1 | -11 | 6 | 8 | 2 | 5 | 6 | |||
| -3 | -5 | -4 | -3 | -17 | -2 | -7 | -3 | -3 | -5 | |||
| 6 | -1 | -1 | 3 | 18 | -6 | -2 | -0 | -1 | -1 | |||
| Net Cash Flow | -0 | -0 | -0 | 0 | -10 | -2 | -0 | -1 | 1 | 1 | ||
| Free Cash Flow | -4 | 3 | 1 | -2 | -28 | 3 | 2 | -0 | 2 | 1 | ||
| CFO/OP | -68% | 162% | 198% | 53% | -198% | 104% | 111% | 43% | 58% | 64% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53 | 107 | 122 | 102 | 109 | 98 | 82 | 92 | 94 | 125 | 138 | 145 |
| Inventory Days | 76 | 63 | 96 | 125 | 74 | 99 | 58 | 76 | 69 | 54 | 90 | 72 |
| Days Payable | 122 | 106 | 112 | 147 | 149 | 143 | 100 | 113 | 108 | 105 | 117 | 119 |
| Cash Conversion Cycle | 6 | 64 | 105 | 80 | 33 | 54 | 39 | 54 | 54 | 75 | 111 | 98 |
| Working Capital Days | 21 | 53 | 110 | 88 | 49 | 61 | 50 | 52 | 54 | 74 | 90 | 87 |
| ROCE % | 10% | 11% | 10% | 9% | 8% | 8% | 10% | 15% | 21% | 21% | 21% | 23% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FOB value of exports Rs crores |
|
|||||||||||
| Number of manufacturing units count |
||||||||||||
| Number of permanent employees count |
||||||||||||
| Number of products count |
||||||||||||
| Top 5 customers concentration % |
||||||||||||
| Installed capacity for capsules million units per month |
||||||||||||
| Installed capacity for dry syrups MT per month |
||||||||||||
| Installed capacity for tablets million units per month |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Clarification On Price Movement
- Company says share price movement is market-driven; no pending disclosures.
-
Financial Results For The Quarter Ended On 30Th June, 2026
- Board approved Q1 FY27 results, reappointed two WTDs, raised MD remuneration, and issued 32nd AGM notice.
-
Board Meeting Intimation for Intimation Of Board Meeting.
- Board meeting on 13 Aug 2026 to approve Q1 FY27 unaudited results.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
- Medico Remedies won USD 1.406 million government supply order from PROMESE/CAL, Dominican Republic, to be completed in 3 months.
-
Clarification sought from Medico Remedies Ltd
- Exchange has sought clarification from Medico Remedies Ltd on August 3, 2026 with reference to significant movement in price, in order to ensure that investors …
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments